Neurotez Inc.
OperatingBiotech · Bridgewater, NJ · Founded 2005
Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.
Financials
FY2015–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Fundraising history
Team
10 people
PhD in Biochemistry at the University of Sussex, UK Founder of Neurotez Inc. 18+ years of biomedical research Two awards from the Alzheimer’s Association, USA Awards from Welcome Trust and Science and Engineering Council, UK 50 publications
PhD in Microbial Biochemistry at University of Cambridge 33 years of drug development experience at Pfizer 50+ publications and patents
MD and PhD in Neuroscience from UCLA 100+ publications on Alzheimer’s disease Senior Research Scientist at the Stanford/VA Aging Clinical Research Center and Alzheimer’s Center
MBA in Finance from Long Island University CEO of Healthcare Economics LLC VP at Dragon Pharmaceuticals, Inc.
PhD in Biochemistry from Imperial College 18+ years of research experience in neural repair and cellular imaging Principal Investigator for the University of Medicine and Dentistry of New Jersey and Albert Einstein College of Medicine
25+ years of pharma experience in US, Canada, and Europe Authored 55 original publications in top-rated international medical journals Member of International Science Advisory Board
MBA in Marketing from the Haub School of Business at Saint Joseph’s University President and CEO of Otsuka America Pharmaceutical, Inc. VP and Global Business Manager for Oncology at Wyeth
Dr Humphries has 36-years experience in Pharma and Biotech with positions at Merck, PharmaKinetics, CSRI (personal start-up CRO), Pharmaco LSR, Applied Bioscience International, Eisai, Ferring, private consulting, Berlex and Bayer.
Show 1 more personShow fewer
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 3 of 9 annual reports (FY2017–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 36 filings on EDGAR- Form C-TRMar 28, 20240001665160-24-000285EDGAR
- Form C-ARFeb 15, 20230001725567-23-000001EDGAR
- Form C/AOct 27, 20220001669191-22-001021EDGAR
- Form C/ASep 12, 20220001669191-22-000888EDGAR
- Form CSep 1, 20220001669191-22-000857EDGAR
- Form C-UAug 31, 20220001665160-22-002333EDGAR
- Form C-ARAug 1, 20220001665160-22-002138EDGAR
- Form C/AFeb 7, 20220001665160-22-000233EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.